
    
      Single centre, double-blind, randomized, placebo-controlled, crossover study with four
      consecutive single-dose treatment periods. The washout period between doses was to be at
      least10 days. On each treatment period (25, 50 and 100 mg BIA 9-1067 or placebo), after
      completion of pre-dose assessments, BIA 9-1067-Placebo was to be administered concomitantly
      with the dose of Madopar HBS; post-dose assessments were to be completed and subjects were to
      be discharged 72 h post-dose.
    
  